Dermatology Articles

• Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma May 31, 2025
  In high-risk cutaneous squamous-cell carcinoma, adjuvant cemiplimab prolonged disease-free survival and reduced recurrence risk as compared with placebo. No new safety concerns with cemiplimab were seen.
  Danny Rischin, Sandro Porceddu, Fiona Day, Daniel P. Brungs, Hayden Christie, James E. Jackson, Brian N. Stein, Yungpo Bernard Su, Rahul Ladwa, Gerard Adams, Samantha E. Bowyer, Zulfiquer Otty, Naoya Yamazaki, Paolo Bossi, Amarnath Challapalli, Axel Hauschild, Annette M. Lim, Vishal A. Patel, Joanna L. Walker, Maite De Liz Vassen Schurmann, Paola Queirolo, Javier Cañueto, Flavio Augusto Ferreira da Silva, Alexander Stratigos, Alexander Guminski, Charles Lin, Fernanda Damian, Lukas Flatz, Anne E. Taylor, David R. Carr, Samuel Harris, Dmitry Kirtbaya, Gaëlle Quereux, Piotr Rutkowski, Nicole Basset-Seguin, Nikhil I. Khushalani, Caroline Robert, Haisong Ju, Camryn Joseph, Shikha Bansal, Chieh-I Chen, Frank Seebach, Suk-Young Yoo, Israel Lowy, Priscila Goncalves, Matthew G. Fury, the C-POST Trial Investigators*
• Insulin-Derived Amyloidosis May 29, 2025
  A 47-year-old man with type 2 diabetes presented with several years of progressive growth of pendulous skin lesions on his lower abdominal wall where he had repeatedly injected insulin.
  Daniel Connors, Philip Chia
• Tufted Angioma with Kasabach–Merritt Phenomenon May 29, 2025
  A full-term baby boy was evaluated at a quaternary care hospital for a large, violaceous, firm, hypertrichotic plaque on the right side of the back. Laboratory studies showed thrombocytopenia and low fibrinogen and elevated d-dimer levels.
  Sarah Servattalab, Pierre-Olivier Grenier